Clinical trials: GENE EXPRESSION
Epithelial Ovarian Cancer, Peritoneal Cancer
A Study of Mirvetuximab Soravtansine in Platinum-Resistant, Advanced High-Grade Epithelial Ovarian, Primary Peritoneal, or Fallopian Tube Cancers With High Folate Receptor-Alpha Expression
This study is designed to evaluate the efficacy and safety of mirvetuximab soravtansine (MIRV) in participants with platinum-resistant high-grade serous epithelial ovarian cancer, primary peritoneal, or fallopian tube cancer…
- Conditions
- Epithelial Ovarian Cancer, Peritoneal Cancer, Fallopian Tube Cancer
- Trial name
- SORAYA (NCT04296890)
- Testing
- Mirvetuximab Soravtansine
- Where
- 89 sites in United States, Australia and 9 more
- Volunteers
- 106 people
- Sponsor
- ImmunoGen, Inc.
Non-small Cell Lung Cancer (NSCLC)
Phase 1b/2 Platform Study of Select Immunotherapy Combinations in Participants With Advanced Non-small Cell Lung Cancer (NSCLC)
This is a Phase 1b/2 study evaluating the anti-PD1 antibody, cemiplimab, in combination with either S095018 (anti-TIM3 antibody), S095024 (anti-CD73 antibody), or S095029 (anti-NKG2A antibody) in adult participants with…
- Trial name
- NCT06162572
- Testing
- S095018, S095024, S095029
- Where
- 52 sites in United States, Australia and 11 more
- Volunteers
- 102 people
- Sponsor
- Servier Bio-Innovation LLC
Myelodysplastic Syndrome
A Phase II Pilot Study to Assess the Presence of Molecular Factors Predictive for Hematologic Response in Myelodysplastic Syndrome Patients Receiving Deferasirox Therapy.
Several previous studies (clinical and non-clinical) hypothesize that treatment with deferasirox causes a hematological improvement in transfused patients with low and intermediate-1 risk myelodysplastic syndrome.
- Trial name
- EXPHAR (NCT02663752)
- Testing
- Bone marrow aspirate, Deferasirox
- Where
- Belgium
- Volunteers
- 1 people
- Sponsor
- Novartis Pharmaceuticals
Lung Cancer, Non-Small Cell
Expression Analysis of Specific Markers in Non-small Cell Lung Cancer or Melanoma
This study intends to analyze the expression of specific sets of markers in tumor samples and in serum from patients with Non-Small Cell lung Cancer (NSCLC) or Stage III or IV melanoma.
- Trial name
- NCT00685750
- Testing
- Collection of tumor and blood samples
- Where
- 34 sites in United States, France and 3 more
- Volunteers
- 88 people
- Sponsor
- GlaxoSmithKline
Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic
Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
This is a two-part study. In Part A, eligible participants will undergo a baseline diagnostic liver biopsy to determine non-alcoholic fatty liver disease (NAFLD) Activity Score (NAS) and fibrosis stage, but will not receive study…
- Conditions
- Non-alcoholic Fatty Liver Disease, Fatty Liver, Nonalcoholic, NAFLD, Nonalcoholic Fatty Liver Disease
- Trial name
- NCT05560607
- Testing
- AZD7503 Intervention
- Where
- United States
- Volunteers
- 19 people
- Sponsor
- AstraZeneca
Dry Eye, Meibomian Gland Dysfunction
IPL and MGX Versus MGX Alone in the Treatment of Dry Eye Disease Secondary to MGD
The aim of the current study is to examine the contribution of intense pulsed light (IPL) for relieving signs and symptoms of dry eye due to meibomian gland dysfunction.
- Trial name
- NCT03265652
- Testing
- Intense Pulsed Light (IPL) therapy
- Where
- Israel
- Volunteers
- 24 people
- Sponsor
- Lumenis Be Ltd.
Melanoma
MElanoma Research Lymph Node Prediction Implementation National_001
MERLIN_001 is a prospective registry study of a primary melanoma gene-signature to predict sentinel node (SN) status and to determine its prognostic value for more accurate staging of SN-negative melanoma patients.
- Trial name
- MERLIN_001 (NCT04759781)
- Where
- 9 sites in United States
- Volunteers
- 1,820 people
- Sponsor
- SkylineDx
Gastric Cancer
Study of DP303c Injection in Patients With Advanced or Metastatic Gastric Cancer
This study is an open-label, multicenter, phase II study to evaluate the efficacy and safety of DP303c injection in patients with HER2-positive advanced or metastatic gastric cancer.
- Trial name
- NCT04826107
- Testing
- DP303c treatment, DP303c treatment（second-line of HER2-positive）, DP303c treatment （third-line of HER2-positive）
- Volunteers
- 196 people
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology Co., Ltd.
Esophageal Squamous Cell Carcinoma
Z650 in Advanced Esophageal Squamous Cell Carcinoma With EGFR Over Expression or Gene Amplification
The purpose of this study is to evaluate the safety and efficacy of Z650 in Advanced Esophageal Squamous Cell Carcinoma patients With EGFR Over expression or Gene Amplification.
- Trial name
- NCT03888092
- Testing
- Z650
- Where
- China
- Volunteers
- 81 people
- Sponsor
- Sunshine Lake Pharma Co., Ltd.
Coronary Artery Disease, Angina Pectoris
Investigation of a Novel Gene Expression Test (ASGES or Corus CAD) for Diagnosis of Obstructive Coronary Artery Disease
The objective of this study is to collect data on the commercial use of Corus CAD (Age/Sex/Gene Expression score - ASGES) blood test to evaluate the clinical referral patterns of Primary Care Physicians after receipt of their…
- Conditions
- Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases
- Trial name
- REGISTRY-I (NCT01557855)
- Testing
- Corus CAD (ASGES)
- Where
- 7 sites in United States
- Volunteers
- 342 people
- Sponsor
- CardioDx
Hepatocellular Carcinoma
Analysis of Expression of Specific Markers and Their Prognostic Significance in Hepatocellular Carcinoma
Hepatocellular carcinoma is an aggressive disease with limited therapeutic options. Therefore, new approaches to treat this type of cancer are needed with immunotherapy potentially being one of these.
- Trial name
- NCT00911196
- Testing
- Retrospective analysis of already archived samples
- Where
- 3 sites in Taiwan, Thailand
- Volunteers
- 200 people
- Sponsor
- GlaxoSmithKline
Healthy, Breast Pumping
Engineering Evaluation of a Breast Pump Device
This research involves feasibility testing of design concepts to support device development of an electric breast pump. The purpose is to evaluate a prototype device for feasibility purposes and not health outcomes.
- Trial name
- NCT05222581
- Testing
- Prototypes of breast shield and Freedom Double Electric Breast Pump
- Where
- United States
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Momtech Inc.
Atherosclerosis
An Experimental Medicine Study to Evaluate Serum Biomarkers of Lipid Metabolism
The purpose of this study is to validate novel assays for serum biomarkers of lipid metabolism (PCSK9 and LDL receptor) and to obtain information about how these biomarkers differ in subjects with normal or high cholesterol levels
- Trial name
- NCT00847782
- Testing
- Blood draw
- Where
- Canada
- Volunteers
- 150 people, healthy volunteers welcome
- Sponsor
- Bristol-Myers Squibb
Leukemia, Acute Myeloid, Myelodysplastic Syndrome
Study of Temozolomide in Previously Untreated Acute Myeloid Leukemia (AML) and Myelodysplastic Syndrome (MDS) Participants With Low O6-Methylguanine Methyltransferase (MGMT) Expression (P05052)
The primary objective of this study is to evaluate the safety, tolerability, and efficacy of temozolomide in acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) participants who are not candidates for standard…
- Trial name
- TALL (NCT00687323)
- Testing
- temozolomide
- Volunteers
- 47 people
- Sponsor
- Merck Sharp & Dohme LLC
Cutaneous Melanoma
Five Year Study to Track Use of DecisionDX-Melanoma Test in Patients With Cutaneous Melanoma and Associated Patient Outcomes
The EXPAND Registry Study follows patients with cutaneous melanoma who have had the DecisionDx-Melanoma gene expression assay performed as part of their clinical care.
- Trial name
- EXPAND (NCT02355587)
- Where
- 4 sites in United States
- Volunteers
- 72 people
- Sponsor
- Castle Biosciences Incorporated
Hepatocellular Carcinoma (HCC), Solid Malignancies
FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression
Estimate the maximum tolerated dose and/or recommended phase II dose and efficacy of FGF401 as single agent and in combination with PDR001 in patients with hepatocellular carcinoma and as single agent in patients with other solid…
- Trial name
- NCT02325739
- Testing
- FGF401, PDR001
- Where
- 27 sites in United States, China and 9 more
- Volunteers
- 172 people
- Sponsor
- Novartis Pharmaceuticals
Cancer - Ovarian
A Study to Evaluate Folate Receptor Alpha (FRα) Expression in Adult Participants With Ovarian, Fallopian Tube, and Primary Peritoneal Cancer in Italy
The purpose of this study is to evaluate the prevalence of folate receptor alpha (FRα)-positive status (≥75% viable tumor cells with moderate (2+) and/or strong (3+) membrane staining) in participants with high-grade serous…
- Trial name
- FORCE (NCT07407062)
- Where
- Italy
- Volunteers
- 200 people
- Sponsor
- AbbVie
HLX07, nsqNSCLC, High EGFR Expression
A Study to Evaluate the Efficacy and Safety of HLX07 in nsqNSCLC Patients With High EGFR Expression
An Open-label, Multicenter , Phase II Clinical Study to Evaluate the Efficacy and Safety of HLX07 (Recombinant Humanized Anti-EGFR Monoclonal Antibody Injection) in Combination with Chemotherapy or Monotherapy in Advanced…
- Trial name
- NCT05215925
- Testing
- HLX07+carboplatin+pemetrexed, HLX07+docetaxel, HLX07
- Where
- China
- Volunteers
- 60 people
- Sponsor
- Shanghai Henlius Biotech
Coronary Artery Disease, Angina Pectoris
Personalized Risk Evaluation and Diagnosis (Using Corus CAD or ASGES) in the Coronary Tree
The PREDICT study is to develop and validate a diagnostic blood ASGES (age, sex, gene expression score) or Corus CAD for atherosclerotic coronary artery disease (CAD).
- Conditions
- Coronary Artery Disease, Angina Pectoris, Chest Pain, Cardiovascular Diseases
- Trial name
- PREDICT (NCT00500617)
- Testing
- Corus CAD (ASGES)
- Where
- 10 sites in United States
- Volunteers
- 4,350 people
- Sponsor
- CardioDx
Alzheimer's Disease, Dementia
Blood Gene Expression Signature in Patients Diagnosed With Probable Alzheimer's Disease Compared to Patients Suffering From Other Types of Dementia
The objective of the study is to define the performance of blood-based signatures for Alzheimer's Disease (AD) in different patients populations including AD, non-AD dementia, and non-demented controls.
- Trial name
- NCT00880347
- Testing
- Blood sampling
- Where
- 21 sites in France
- Volunteers
- 550 people, healthy volunteers welcome
- Sponsor
- Exonhit